Antisense oligonucleotides: local delivery enhances their therapeutic potential

Bibliography

• CROOKE ST: An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev. (1998) 8(2):115–122.
   PubMedGoogle Scholar
• AGRAWAL S, ZHAO Q: Antisense therapeutics. Cur. Opin. Chem. Biol. (1998) 2 (4) :519–528.
   PubMedGoogle Scholar
• MAR WICK C: First `antisense' drug will treat CMV retini-tis. JAMA (1998) 280(10):871.
   PubMedGoogle Scholar
• LEEDS JM, HENRY SP, BISTNER S, SCHERRILL S, WILLIAMS K, LEVIN, AA: Pharmacokinetics of an antisense oligo-nucleotide injected intravitreally in monkeys. Drug Metab. Dispos. (1998) 26(7):670–675.
   PubMedGoogle Scholar
• •First pharmacokinetics report for a locally delivered ASON.
   Google Scholar
• CHOI BM, KWAK HJ, JUN CD, PARK SD, KIM HR, CHUNG HT: Control of scarring in adult wounds using an-tisense transforming growth factor beta 1 oligode-oxynucleotides. Immunol Cell Biol. (1996) 74 (2) :144–150.
   PubMedGoogle Scholar
• CASELMANN WH, EISENHARDT S, ALT M: Synthetic an-tisense oligodeoxynucleotides as potential drugs against hepatitits C. Intervirology (1998) 40 (5-6) 394–399.
   Google Scholar
• HE Y, HUANG L: Growth inhibition of human papillo-mavirus 16 DNA-positive mouse tumor by antisense RNA transcribed from U6 promoter. Cancer Res. (1997) 57 (18) 3993–3999.
   PubMedGoogle Scholar
• MADRIGAL M, JANICEK MF, SEVIN BU et al.: In vitro anti-gene therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecol Oncol (1997) 64 (1) :18–25.
   PubMedGoogle Scholar
• VON DER LEYDEN HE, MANN MJ, DZAU VJ: Gene inhibi-tion and gene augmentation for the treatment of vas-cular proliferative disorders. Semin. Interv. Cardiol. (1996) 1(3):209–214.
   PubMedGoogle Scholar
• KANEDA Y, MORISHITA R, DZAU VJ: Prevention of res-tenosis by gene therapy. Ann. NY Acad. ScL (1997) 811:299–308.
   PubMed Web of Science ®Google Scholar
• POSTON RS, TRAN KP, MANN MJ, HOYT EG, DZAU VJ, ROBBINS RC: Prevention of ischemically induced neointimal hyperplasia using ex vivo antisense oli-godeoxynucleotides. J. Heart Lung Transplant (1998) 17 (4):349–355.
   PubMedGoogle Scholar
• MORISHITA R, GIBBONS GH, ELLISON KE et al: Single in-traluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperpla- sia. Proc. Natl. Acad. Sci. USA (1993) 90(18):8474–8.
   PubMed Web of Science ®Google Scholar
• •Along with references 9–11, provides seminal descriptions of the potential for ex vivo ASON intervention as an adjunct to surgical procedures.
   Google Scholar
• STEPKOWSKI SM: Antisense oligodeoxynucleotides fororgan transplantation. Gin. Biochem. (1998) 31(5):375–379.
   Google Scholar
• STEPKOWSKI SM, WANG ME, CONDON TP et al.: Protec-tion against allograft rejection with intracellular adhe-sion molecule 1 antisense oligodeoxynucleotides. Transplantation (1998) 66(6)699–707.
   Google Scholar
• BENNETT CF: ICAM-1 antisense oligonucleotides. Curr. Res. Mol. Ther. (1998) 1(2):85–92.
   Google Scholar
• NYCE JW AND METZGER WJ: DNA antisense therapy forasthma in an animal model. Nature (1997) 385:721–725.
   PubMedGoogle Scholar
• •Ground breaking work on respirable ASONs. First demon-stration that the lung is a uniquely receptive organ for ASON disease intervention.
   Google Scholar
• NICKLIN PI, BAYLEY D, GIDDINGS J et al Pulmonary bioavailability of a phosphorothioate olignucleotide (CGP 41280 Comparison with other delivery routes. Pharma. Res. (1998) 15 (4) 583–591
   Google Scholar
• HAKONARSON H, SHANBAKY I, GUERRA FM GRUNSTEIN MM: Modulation of adenosine Ai, bradykinin Bi, and histamine Hi receptor expression and function in atopic asthmatic sensitized airway smooth muscle. Proc. Amer. Thoracic Society, International Congress, Chi-cago, C56 (1998).
   Google Scholar
• NIE G: Oxidative stress increases Ai adenosine recep-tor expression by activating Nuclear Factor Kappa B. Mol. Pharmacol. (1998) 53:663–669.
   PubMedGoogle Scholar
• LIU M, WANG L, HOLM BA, ENHORNING G: Surfactant depletion in asthma. Clin. Exp. Allergy (1997) 27:802–807.
   PubMedGoogle Scholar
• HAMM H, FABEL H, BARSCH W:Surfactant. Clin. Invest. (1992) 70:637–657.
   PubMedGoogle Scholar
• GRIESE M, GOBRAN L, DOUGLAS J, ROONEY, S: Adeno-sine Ay receptor-mediated phosphatidylcholine secre-tion in Type II pneumocytes. Am. J. Physiol. (1991) 260(2 Pt 1)152–60.
   Google Scholar
• GOBRAN L, ROONEY S: Adenosine Ai receptor-mediated inhibition ofsurfactant secretion. Am. J. Physiol. (1990) 258(2:1)145–51.
   Google Scholar
• DIXON AK, GUBITZ AK, SIRINATHSINGHJI DJS, RICH-ARDSON PJ, FREEMAN TC: Tissue distribution of adeno-sine receptor mRNAs in the rat. Br. J. Pharmacol. (1996) 118:1461–1468.
   PubMed Web of Science ®Google Scholar
• BJORCK T: Isolated bronchi from asthmatics are hyper-responsive to adenosine, which apparently acts by lib-eration of leukotrienes and histamine. Am. Rev. Resp. Dis. (1992) 145:1087–1090.
   PubMed Web of Science ®Google Scholar
• ALI S, MUSTAFFA SM, METZGER WJ: Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: Evidence for an inducible adeno-sine Ai receptor. JPET (1994) 268 (3) :1328–1334.
   PubMedGoogle Scholar
• NYCE JW:Insight into adenosine receptor function us-ing antisense and gene knock out approaches. TIPS (1999) March. (In Press.)
   Google Scholar
• BOADO RJ, TSUKAMOTO H, PARDRIDGE WM: Drug de-livery of antisense molecules to the brain for treat-ment of Alzheimer's disease and cerebral AIDS. J. Pharm. Sci. (1998) 87(10:1308–1315.
   PubMedGoogle Scholar
• MULAMBA GB, HU A, AZAD RF, ANDERSON KP, COEN DM: Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligo-nucleotide fomivirsen (ISIS 2924 Antimicrob. Agents Chemother. (1998) 42(4):971–973.
   PubMedGoogle Scholar